Renaissance Capital logo

Sequoia Vaccines Filed Terms, NYSE American: SQVI

Phase 1 biotech developing a vaccine for recurrent UTIs and small molecules for cancers.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urinary tract infections (UTIs) and small molecules for treating cancers and bacterial infections. Our lead clinical candidate, SEQ-400, is a vaccine under investigation for the prevention of recurrent UTIs, which received fast track designation by the Food and Drug Administration (FDA) in December 2017. We are planning a UTI observation trial in 2023 which will seek to identify and define a population of patients with culture-verified recurrent UTIs to participate in a subsequent phase 2 efficacy trial of SEQ-400 where enrolled patients will serve as their own control comparing UTI occurrences pre and post vaccination with SEQ-400. SEQ-400 is designed to generate antibodies that function to reduce the bacterial attachment and colonization of human bladders to prevent UTIs. We successfully completed a phase 1 study which studied the tolerance and immunogenicity of the adjuvanted vaccine in a population of healthy volunteers and women with a history of recurrent UTIs. This study established a recommended phase 2 dose and schedule. The next step in SEQ-400’s development is to conduct a phase 2 clinical trial to evaluate efficacy in a defined population of patients with culture-verified recurrent UTIs.
more less
IPO Data
IPO File Date 11/06/2023
Offer Price
Price Range $8.00 - $10.00
Offer Shares (mm) 2.8
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $8.00 - $10.00
Offer Shares (mm) 2.8
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
ThinkEquity
Company Data
Headquarters St. Louis, MO, United States
Founded 2012
Employees at IPO 11
Website www.sequoiavaccines.com

Sequoia Vaccines (SQVI) Performance